Immediate Impact
1 by Nobel laureates 61 standout
Citing Papers
Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Rachel E. Lerner being referenced
Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).
2020
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS)
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Rachel E. Lerner | 74 | 50 | 122 | 93 | 17 | 325 | |
| Kaori Wada | 30 | 44 | 30 | 45 | 34 | 328 | |
| Christine Schmid | 42 | 35 | 65 | 52 | 11 | 278 | |
| John A. Axelson | 21 | 64 | 79 | 26 | 17 | 298 | |
| Marco Rizzo | 31 | 27 | 55 | 67 | 28 | 321 | |
| Georgios Papageorgiou | 15 | 33 | 78 | 34 | 35 | 319 | |
| Faye Antoniou | 31 | 10 | 67 | 40 | 30 | 362 | |
| Xi Zhu | 19 | 24 | 76 | 48 | 38 | 337 | |
| Jessica Rhee | 17 | 51 | 140 | 32 | 10 | 315 | |
| Jin‐Hwa Moon | 18 | 10 | 56 | 39 | 31 | 347 | |
| Matthew Welch | 20 | 69 | 88 | 22 | 22 | 357 |
All Works
Login with ORCID to disown or claim papers
Loading papers...